Journal
DRUG DISCOVERY TODAY
Volume 12, Issue 17-18, Pages 748-756Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2007.07.008
Keywords
-
Categories
Ask authors/readers for more resources
The serotonin 5-HT1A receptor is implicated in the pathophysiology of major neuropsychiatric disorders, including depression, suicidal behavior, panic disorder, epilepsy, bulimia, schizophrenia, Parkinson's disease, and Alzheimer's disease and is, therefore, an important target for drug therapy. 5-HT1A receptors are expressed as somatodendritic autoreceptors in serotonin neurons of the raphe nuclei (presynaptic) and as postsynaptic receptors in cortical and subcortical serotonin terminal fields in the brain. Due to the higher concentration and heterogeneous distribution of this receptor, it is an attractive target for quantification in vivo using positron emission tomography (PET) and single photon emission tomography (SPECT). Here, we review the PET radioligands employed for imaging 5-HT1A receptors in living brain.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available